Dose-response improvements in glycaemic control and body weight reduction with HM11260C, a once weekly GLP-1 receptor agonist with liraglutide as reference, in type 2 diabetes.[abstract]
It is critically important to note that retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
The GLP-1 analogues market is growing rapidly due to the increasing incidence of diabetes and obesity in the world, which is fueling a high demand for treatments that can efficiently control body weight and blood sugar
Prior authorization itself has become a significant barrier
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al